Cite
MLA Citation
E.M. Stein et al.. “Enasidenib (AG-221), A Selective Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, In Patients with Myelodysplastic Syndromes (MDS).” Leukemia research, vol. 55, n.d., pp. S24–S25. http://access.bl.uk/ark:/81055/vdc_100045920464.0x000045